Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

COVID-19: Outpatient Therapeutic Updates

New data have emerged regarding treatment principles and therapeutic options for nonhospitalized adult and pediatric patients with COVID-19. Hear a faculty expert describe treatment options and treatments to avoid.
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: May 24, 2022

In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses:

  • Principles for antiviral agent use in nonhospitalized patients
  • Preferred and alternative treatment options
  • Treatment prioritization when there are logistical or supply constraints
  • Outpatient remdesivir use
  • PINETREE data (adult patients)
  • CARAVAN data (pediatric patients)
  • FDA approval and treatment candidacy
  • Therapeutic updates
  • Ivermectin and the TOGETHER study
  • Monoclonal antibody use during current omicron era

Information on this Educational Activity

Faculty

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Related Content

Download slides reviewing the latest data and guidance on COVID-19 vaccinations, including authorized and investigational agents, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: August 8, 2022

Expert insights on oral antiviral efficacy in real-world populations and COVID-19 rebound phenomenon, from Clinical Care Options (CCO)

Arthur Kim, MD Released: August 5, 2022

Dr Renslow Sherer discusses COVID-19 vaccine updates, including a new, non-mRNA vaccine and pediatric recommendations, from Clinical Care Options (CCO)

Renslow Sherer, MD Released: August 1, 2022

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings